<DOC>
	<DOCNO>NCT00612703</DOCNO>
	<brief_summary>To determine safety , tolerability recommend Phase 2 dose ARQ 197 administer combination erlotinib patient advance solid tumor</brief_summary>
	<brief_title>A Phase 1 Study ARQ 197 Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Signed write informed consent must obtain document accord International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) , local regulatory requirement , permission use private health information accordance Health Insurance Portability Accountability Act ( HIPPA ) prior studyspecific screening procedures A histologically cytologically confirm solid tumor advance , metastatic , and/or inoperable follow prior standard chemotherapy , and/or , opinion investigator , alternative therapy , monotherapy erlotinib appropriate ≥ 18 year age Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within four week first dose ( patient currently erlotinib monotherapy may enrol study without washout ) Major surgery within 4 week prior first dose Central nervous system metastasis unless stable ≥ 3 month treatment patient neural symptom Pregnant breastfeed Significant gastrointestinal disorder , opinion Investigator , could interfere absorption ARQ 197 and/or erlotinib ( e.g . significant , uncontrolled inflammatory bowel disease extensive small bowel resection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer , oral , erlotinib , tarceva , solid tumor , advanced tumor , phase 1</keyword>
	<keyword>Tumor</keyword>
</DOC>